CRMD - After shares more than double in a month CorMedix takes a breather

Shares of CorMedix Inc. (CRMD) are down 13% in morning trading.Shares of the infectious and inflammatory diseases focused biopharma have been on a tear, gaining 124% in the last month and 89% in the last 5 days alone.The stock's bullishness appears centered on the CorMedix's lead candidate, Defencath.Taurolidine, Defencath's key component, is a synthetic, broad-spectrum antimicrobial and antifungal drug with anti-inflammatory and potential anti-tumor action.Defencath's NDA is for the prevention of catheter related blood stream infections, or CRBSIs, in patients undergoing hemodialysis via central venous catheter.Defencath has an FDA PDUFA date of Feb. 28, 2021.Shares are down 13% to $14.39 in morning trading.

For further details see:

After shares more than double in a month, CorMedix takes a breather